FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149359025> ?p ?o ?g. }

• W2149359025 abstract "Alpha-glucosidase inhibitors (AGIs) reduce blood glucose levels and may thus prevent type 2 diabetes and cardiovascular disease in patients with impaired glucose tolerance. These possible effects, and the effects on quality of life, plasma lipids and body weight, have never been investigated in a systematic literature review and meta-analysis.To assess the effects of alpha-glucosidase inhibitors in patients with impaired glucose tolerance (IGT) or impaired fasting blood glucose (IFBG), or both.We searched The Cochrane Library (Clinical Trials database, formerly known as CENTRAL), PUBMED, EMBASE, Web of Science, LILACS, databases of ongoing trials, reference lists of relevant reviews, and we contacted experts and manufacturers. Date of last search was February 2006.Randomised controlled trials of at least one-year duration in patients with IGT or IFBG, or both, comparing AGI monotherapy with any other intervention.Two reviewers read all abstracts, assessed quality and extracted data independently. Discrepancies were resolved by consensus or by the judgement of a third reviewer.We included five trials (2360 participants), all investigating acarbose, that included patients with IGT or patients 'at increased risk for diabetes' (n = 1). Study duration was one, three (n = 2), five and six years. One study was at low risk of bias and four studies at high risk of bias. Except for the outcome incidence of type 2 diabetes in acarbose versus no treatment (two studies), meta-analyses were not possible. Data from the study at low risk of bias suggests that acarbose decreases the occurrence of type 2 diabetes (NNT = 10), cardiovascular events (NNT = 50, based on 47 events, study not initially powered for this outcome), post-load blood glucose (-0.6 mmol/L, 95% CI -1.0 to -0.3) and body mass index (0.3 kg/m(2), 95% CI -0.1 to -0.5). No statistically significant effects were observed on mortality, other morbidity, glycated haemoglobin, fasting blood glucose, lipids and blood pressure. The effects on the incidence of type 2 diabetes were confirmed in two studies at high risk of bias (OR 0.2, 95% CI 0.1 to 0.6). Adverse effects were mostly of gastro-intestinal origin (OR 3.5, 95% CI 2.7 to 4.4).There is evidence that acarbose reduces the incidence of type 2 diabetes in patients with IGT. However, it is unclear whether this should be seen as prevention, delay or masking of diabetes. Acarbose may prevent the occurrence of cardiovascular events, but this finding needs to be confirmed in more studies." @default.
• W2149359025 created "2016-06-24" @default.
• W2149359025 creator A5047798210 @default.
• W2149359025 creator A5053320862 @default.
• W2149359025 creator A5054061923 @default.
• W2149359025 creator A5069689717 @default.
• W2149359025 creator A5089374882 @default.
• W2149359025 date "2006-10-18" @default.
• W2149359025 modified "2023-09-26" @default.
• W2149359025 title "Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose" @default.
• W2149359025 cites W1491013031 @default.
• W2149359025 cites W1550583055 @default.
• W2149359025 cites W1964435302 @default.
• W2149359025 cites W1973567825 @default.
• W2149359025 cites W1982045848 @default.
• W2149359025 cites W1992777999 @default.
• W2149359025 cites W2013859236 @default.
• W2149359025 cites W2023807105 @default.
• W2149359025 cites W2024689627 @default.
• W2149359025 cites W2031968478 @default.
• W2149359025 cites W2038609397 @default.
• W2149359025 cites W2053154970 @default.
• W2149359025 cites W2053591250 @default.
• W2149359025 cites W2068036151 @default.
• W2149359025 cites W2083342497 @default.
• W2149359025 cites W2087536878 @default.
• W2149359025 cites W2087866400 @default.
• W2149359025 cites W2087875612 @default.
• W2149359025 cites W2106734747 @default.
• W2149359025 cites W2123744385 @default.
• W2149359025 cites W2126930838 @default.
• W2149359025 cites W2132594773 @default.
• W2149359025 cites W2134235461 @default.
• W2149359025 cites W2134293572 @default.
• W2149359025 cites W2134455173 @default.
• W2149359025 cites W2146536851 @default.
• W2149359025 cites W2152265658 @default.
• W2149359025 cites W2157823046 @default.
• W2149359025 cites W2158822657 @default.
• W2149359025 cites W2159865972 @default.
• W2149359025 cites W2185461071 @default.
• W2149359025 cites W2332951586 @default.
• W2149359025 cites W3144292100 @default.
• W2149359025 cites W3152288477 @default.
• W2149359025 cites W4233562854 @default.
• W2149359025 cites W4241510137 @default.
• W2149359025 cites W4243841175 @default.
• W2149359025 doi "https://doi.org/10.1002/14651858.cd005061.pub2" @default.
• W2149359025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17054235" @default.
• W2149359025 hasPublicationYear "2006" @default.
• W2149359025 type Work @default.
• W2149359025 sameAs 2149359025 @default.
• W2149359025 citedByCount "71" @default.
• W2149359025 countsByYear W21493590252012 @default.
• W2149359025 countsByYear W21493590252014 @default.
• W2149359025 countsByYear W21493590252015 @default.
• W2149359025 countsByYear W21493590252016 @default.
• W2149359025 countsByYear W21493590252017 @default.
• W2149359025 countsByYear W21493590252018 @default.
• W2149359025 countsByYear W21493590252019 @default.
• W2149359025 countsByYear W21493590252020 @default.
• W2149359025 countsByYear W21493590252021 @default.
• W2149359025 countsByYear W21493590252022 @default.
• W2149359025 countsByYear W21493590252023 @default.
• W2149359025 crossrefType "journal-article" @default.
• W2149359025 hasAuthorship W2149359025A5047798210 @default.
• W2149359025 hasAuthorship W2149359025A5053320862 @default.
• W2149359025 hasAuthorship W2149359025A5054061923 @default.
• W2149359025 hasAuthorship W2149359025A5069689717 @default.
• W2149359025 hasAuthorship W2149359025A5089374882 @default.
• W2149359025 hasBestOaLocation W21493590252 @default.
• W2149359025 hasConcept C126322002 @default.
• W2149359025 hasConcept C134018914 @default.
• W2149359025 hasConcept C168563851 @default.
• W2149359025 hasConcept C2776478404 @default.
• W2149359025 hasConcept C2776617576 @default.
• W2149359025 hasConcept C2777180221 @default.
• W2149359025 hasConcept C2777185836 @default.
• W2149359025 hasConcept C2780439572 @default.
• W2149359025 hasConcept C2780609358 @default.
• W2149359025 hasConcept C555293320 @default.
• W2149359025 hasConcept C71924100 @default.
• W2149359025 hasConcept C95190672 @default.
• W2149359025 hasConceptScore W2149359025C126322002 @default.
• W2149359025 hasConceptScore W2149359025C134018914 @default.
• W2149359025 hasConceptScore W2149359025C168563851 @default.
• W2149359025 hasConceptScore W2149359025C2776478404 @default.
• W2149359025 hasConceptScore W2149359025C2776617576 @default.
• W2149359025 hasConceptScore W2149359025C2777180221 @default.
• W2149359025 hasConceptScore W2149359025C2777185836 @default.
• W2149359025 hasConceptScore W2149359025C2780439572 @default.
• W2149359025 hasConceptScore W2149359025C2780609358 @default.
• W2149359025 hasConceptScore W2149359025C555293320 @default.
• W2149359025 hasConceptScore W2149359025C71924100 @default.
• W2149359025 hasConceptScore W2149359025C95190672 @default.
• W2149359025 hasLocation W21493590251 @default.
• W2149359025 hasLocation W21493590252 @default.
• W2149359025 hasLocation W21493590253 @default.
• W2149359025 hasLocation W21493590254 @default.
• W2149359025 hasOpenAccess W2149359025 @default.

• next